



Joint Working Executive Summary

Published on www.bayer.co.uk

Project title	Redesign of Macular Service at Taunton & Somerset NHS Foundation Trust
Project partners	Taunton & Somerset Hospital NHS Foundation Trust Bayer plc
Project summary	<p>The ophthalmology department at Taunton Hospital, part of Taunton & Somerset Hospital NHS Foundation Trust, is facing a number of issues with capacity to deliver its services therefore a service redesign is being proposed to address these capacity issues.</p> <p>The project will involve:</p> <ul style="list-style-type: none">• Training for appropriate HCPs in the use of new imaging technology, and to give treatment to patients according to agreed pathways• Implementation of new technology to allow improvements in the management of specific patient groups• Implementation of recognised quality improvement methodologies to continuously develop and improve services to optimise outcomes for patients• Initiation of virtual clinics for medical retina patients, as well as for patients referred from the diabetic screening service and additional macular treatment <p>These changes will be implemented by the redesign of patient pathways and embedded via the use of improvement methodologies.</p>
Expected benefits to patients, the NHS and Bayer	<p>Benefits for Patients:</p> <ul style="list-style-type: none">• Timely and convenient access to treatment following diagnosis• Better patient experience in streamlined Reverse Virtual Anti-VEGF clinics• The potential to improve outcomes by being treated according to national guidelines• Access to additional diagnostic equipment and improved clinical pathways at the local hospital will mean fewer out of area referrals and therefore facilitate more care closer to home for patients <p>Benefits for the NHS:</p> <ul style="list-style-type: none">• Virtual review of patient referrals from Regional and National Screening Programmes will reduce waiting times for these patients and enable rapid diagnosis and appropriate treatment according to national guidelines

	<ul style="list-style-type: none"> • Workforce redesign in conjunction with pathway redesign will allow the Trust to manage resources effectively to optimise patient outcomes • The addition of new technology will reduce the number of out of area referrals <p>Benefits for Bayer:</p> <ul style="list-style-type: none"> • Improved reputation by demonstrating commitment and willingness to invest in improving patient care through a fully transparent joint working agreement with Taunton & Somerset • Improving NICE-approved medicines optimisation of injectable therapies, of which Bayer’s aflibercept is one, in line with national guidelines due to improving capacity for provision • Better understanding of Taunton & Somerset and patients’ needs
Start date	October 2017

Date of Preparation: May 2019

Job bag number: PP-OTH-GB-0191